Development of AS01b Mimics by Replacing QS-21 with a New Saponin Adjuvant

用新型皂苷佐剂替代 QS-21 开发 AS01b 模拟物

• 批准号: 10691629
• 负责人: SUZANNE MICHALEK
• 金额: $ 60万
• 依托单位: ADJUVAX LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-30 至 2024-08-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10691629
• 关键词: Address; Adjuvant; Antigens; Development; FDA approved; Formulation; Herpesvirus Type 3; Immunity; Nature; QS21; Saponins; Side; Vaccines; efficacy testing; novel; novel vaccines; preclinical study

AS01b (composed of the molecules QS-21 and MPL) is a powerful adjuvant best known for being a component of the FDA-approved Shingrix vaccine. Despite its successful track-record as an effective adjuvant, accessibility to AS01b as an adjuvant for use in novel vaccines is a concern due to the limited nature of the saponin molecule QS-21. The awardee seeks to address this problem by developing a mimic of AS01b by replacing QS-21 with a novel saponin molecule.

AS01b(由QS-21和MPL分子组成)是一种强大的佐剂，因其是FDA批准的Shingrix疫苗的组成部分而闻名。尽管AS01b作为一种有效的佐剂有成功的记录，但由于皂素分子QS-21的有限性质，AS01b作为新型疫苗佐剂的可及性是一个令人担忧的问题。获奖者试图通过用一种新的皂素分子取代QS-21来开发一种AS01b的模拟物来解决这个问题。